Literature DB >> 12912731

Isoniazid for latent tuberculosis infection: approaching 40 and reaching its prime.

Charles M Nolan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12912731     DOI： 10.1164/rccm.2306004

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  3 in total

1.  Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity.

Authors:  Paul H Hayashi; Robert J Fontana; Naga P Chalasani; Andrew A Stolz; Jay A Talwalkar; Victor J Navarro; William M Lee; Timothy J Davern; David E Kleiner; Jiezhun Gu; Jay H Hoofnagle
Journal:  Clin Gastroenterol Hepatol       Date:  2015-02-24       Impact factor: 11.382

2.  Cost-effectiveness of QuantiFERON-TB Gold In-Tube versus tuberculin skin test for diagnosis and treatment of Latent Tuberculosis Infection in primary health care workers in Brazil.

Authors:  Rafaela Borge Loureiro; Ethel Leonor Noia Maciel; Rosangela Caetano; Renata Lyrio Peres; Geisa Fregona; Jonathan E Golub; José Ueleres Braga
Journal:  PLoS One       Date:  2019-11-14       Impact factor: 3.240

3.  Cost-effectiveness of Quantiferon®-TB Gold-in-Tube versus tuberculin skin testing for contact screening and treatment of latent tuberculosis infection in Brazil.

Authors:  Ricardo Ewbank Steffen; Rosângela Caetano; Márcia Pinto; Diogo Chaves; Rossini Ferrari; Mayara Bastos; Sandra Teixeira de Abreu; Dick Menzies; Anete Trajman
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.